Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Ann Rheum Dis
; 79(6): 800-810, 2020 06.
Article
in En
| MEDLINE
| ID: mdl-32234715
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Osteoarthritis, Hip
/
Osteoarthritis, Knee
/
Musculoskeletal Pain
/
Antibodies, Monoclonal, Humanized
/
Analgesics
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Rheum Dis
Year:
2020
Type:
Article
Affiliation country:
France